The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)

Not Applicable

Completed

• Conditions: Lymphatic Disease; HIV Infections

• Registration Number: NCT00002048
• Lead Sponsor: Glaxo Wellcome

Brief Summary

To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) in HIV-infected adult patients without clinical manifestations of disease. To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (22)

LaJolla Veterans Administration Med Ctr; 🇺🇸 LaJolla, California, United States

AIDS Clinical Trials Group; 🇺🇸 San Diego, California, United States

Georgetown Univ Med Ctr; 🇺🇸 Washington, District of Columbia, United States

Univ of Miami School of Medicine; 🇺🇸 Miami, Florida, United States

Univ of South Florida; 🇺🇸 Tampa, Florida, United States

Emory Univ School of Medicine; 🇺🇸 Atlanta, Georgia, United States

Univ of New Mexico Hlth Sciences Ctr / Dept of Med; 🇺🇸 Albuquerque, New Mexico, United States

Northshore Hosp / Cornell Univ; 🇺🇸 Manhasset, New York, United States

Nalle Clinic; 🇺🇸 Charlotte, North Carolina, United States

Bowman Gray School of Medicine / North Carolina Baptist Hosp; 🇺🇸 Winston Salem, North Carolina, United States

Scroll for more (12 remaining)